Novartis scores FDA nod for game-changing SMA treatment
Itvisma is a one-time, fixed-dose therapy designed to tackle the genetic root cause of SMA
Itvisma is a one-time, fixed-dose therapy designed to tackle the genetic root cause of SMA
The European Commission’s green light marks Breyanzi’s fourth indication in Europe and extends access to patients across all EU and EEA countries
Solventum aims to accelerate innovation in acute wound care, expand its market reach, and deliver enhanced solutions for patients, clinicians, and shareholders
Data show adjuvant Verzenio plus endocrine therapy extends overall survival and sustains long-term improvements in invasive disease-free survival
Jaypirca is making waves in the fight against B-cell malignancies
The collaboration aims to make Alzheimer’s biomarker testing more accessible and less intimidating
Abbott is eyeing to become a global powerhouse in early cancer detection and precision oncology
Subscribe To Our Newsletter & Stay Updated